Fig. 4.
Fig. 4. The F-104 epitope in fibrinogen includes a plasmin cleavage site as visualized by immunoblotting with MoAb F-102 (anti-Aα 563-578). Purified fibrinogen was digested with plasmin (see Fig 3 legend) either without (left) or with (right) an initial MoAb F-104 preincubation step. PVDF transfers from 12.5% SDS-PAGE (nonreduced) were subjected to immunoblotting with MoAb F-102; 9.6 μg (56 pmol Aα chain equivalents) of intact or plasmin-treated fibrinogen were applied to each lane. At this load application, COOH-terminal Aα chain degradation products present at low level in the starting fibrinogen preparation are visualized in the T0 lanes. The high molecular weight material at the top of the lanes in the right panel reflects the F-104 IgG added during the preincubation step (16.8 μg, 113 pmol IgG/lane).

The F-104 epitope in fibrinogen includes a plasmin cleavage site as visualized by immunoblotting with MoAb F-102 (anti-Aα 563-578). Purified fibrinogen was digested with plasmin (see Fig 3 legend) either without (left) or with (right) an initial MoAb F-104 preincubation step. PVDF transfers from 12.5% SDS-PAGE (nonreduced) were subjected to immunoblotting with MoAb F-102; 9.6 μg (56 pmol Aα chain equivalents) of intact or plasmin-treated fibrinogen were applied to each lane. At this load application, COOH-terminal Aα chain degradation products present at low level in the starting fibrinogen preparation are visualized in the T0 lanes. The high molecular weight material at the top of the lanes in the right panel reflects the F-104 IgG added during the preincubation step (16.8 μg, 113 pmol IgG/lane).

Close Modal

or Create an Account

Close Modal
Close Modal